Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

[ad_1] SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ — Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the…

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

[ad_1] SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom’s Medicines and Healthcare Products Regulatory…

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion

[ad_1] The deal expands the pharmaceutical company’s portfolio of cancer drugs. [ad_2] Source link

Paramours, Pilots and a Poker Pal: Longtime Tottenham Owner Allegedly Shared Insider-Trading Tips

[ad_1] Joe Lewis, the 86-year-old billionaire whose family trust now controls the English soccer team, is a defendant in New York. [ad_2] Source link

WSJ News Exclusive | New Drugs for Cancer, Rare Disease Can Now Cost More Than $20,000 a Month

[ad_1] WSJ News Exclusive Health Trend follows rising pressure on companies to rein in repeat or annual price hikes for older drugs [ad_2] Source link